Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 129-2 (miR-129-2)
- Target
- miR-129-2
- Molecular classification
- MicroRNA, Non-coding RNA, Regulatory RNA
01
Overview
MicroRNA 129-2 is a non-coding RNA gene that produces regulatory microRNAs (miR-129-3p and miR-129-5p) involved in post-transcriptional regulation of gene expression[4][3]. These microRNAs bind to complementary sequences in the 3' untranslated regions (3' UTRs) of target mRNAs, leading to mRNA degradation or translation inhibition. miR-129-2 is located on chromosome 11p11.2 and functions as a tumor suppressor in multiple cancer types by regulating genes involved in cell cycle, apoptosis, proliferation, migration, and drug resistance[1][3]. Additionally, miR-129-2 plays important roles in neuronal development, cardiovascular health, and metabolic diseases. It is downregulated in various malignancies and some non-cancer diseases, making it a potential therapeutic target and biomarker for disease diagnosis and prognosis[1][3][2][4].
- Other names
- hsa-mir-129-2MIRN129-2MIR129-2mir-129-2MIR-129b
02
Mechanism of action
Oligonucleotide-based approaches (e.g., miRNA mimics or inhibitors) regulating the expression of miR-129-2 to modulate its downstream effects
03
Biological functions
Post-transcriptional gene regulationRegulation of cell cycleRegulation of apoptosisRegulation of cell proliferationRegulation of cell migration and invasionNeuronal development and migration
04
Disease associations
Cancer (e.g., ovarian, prostate, nasopharyngeal, lung, breast, colorectal, hepatocellular, bladder, endometrial)Drug resistance (e.g., in cancer)Neurodegenerative disease (e.g., Alzheimer's disease)Cardiovascular disease (e.g., heart failure)DiabetesEpilepsyObesityIntervertebral disc degeneration
05
Safety considerations
Potential off-target effects when modulating miRNA pathwaysDelivery challenges for nucleic acid-based therapeutics targeting miRNA[3]
06
Biomarkers
Tissue or fluid levels of miR-129-2 (including miR-129-3p and miR-129-5p) for diagnosis, prognosis, or treatment response in cancers and non-cancer diseases such as diabetes and epilepsy[3]
Beyond the preview
Go deeper on MicroRNA 129-2 (miR-129-2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroRNA 129-2 (miR-129-2).